Assessment of Metabolic Complications in Patients With Adrenal Tumors Through Radiological Images
Launched by IRCCS AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA · Jan 24, 2025
Trial Information
Current as of August 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating how adrenal tumors, which are growths on the adrenal glands, might be linked to metabolic complications, such as issues with how the body processes energy. The researchers will analyze CT images that have already been taken of patients who had adrenal tumors and either had surgery to remove them or were diagnosed as benign (non-cancerous). By looking at these images, the study aims to better understand the relationship between adrenal tumors and metabolic health.
To be eligible for this study, participants must be at least 18 years old and have had an adrenal tumor diagnosed between January 1, 2000, and May 30, 2023. They should have undergone surgery to remove the tumor or have a benign tumor that has shown no changes over time. Participants will need to provide consent for their CT images to be used in the research. Since this study is looking at past patient data, there are no additional treatments or procedures involved, making it a safe way to contribute to important research without any direct risks to participants.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥18 years
- • Patients with adrenal tumor who underwent adrenectomy surgery from 1-1-2000 to 30-5-2023, performed according to clinical necessity and indications of international guidelines,with availability of histologic diagnosis or adrenal tumor that did not undergo adrenectomy surgery with diagnosis of benignity confirmed by radiologic stability at 6-12 months after first finding(as indicated in guidelines)
- • Availability of radiological images in DICOM format of abdominal CT scan in which the adrenal tumor is first described, obtained on the date of first evaluation at the participating center (necessarily before surgery for patients undergoing adrenectomy)
- • Signature of informed consent
- Exclusion Criteria:
- • none
About Irccs Azienda Ospedaliero Universitaria Di Bologna
IRCCS Azienda Ospedaliero-Universitaria di Bologna is a prestigious research and healthcare institution in Italy, renowned for its commitment to advancing medical science and patient care through innovative clinical research. As an IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), it integrates clinical practice with scientific research, facilitating the translation of laboratory findings into effective treatment strategies. The institution fosters a multidisciplinary approach, collaborating with various experts to conduct high-quality clinical trials aimed at improving health outcomes across a wide range of medical fields. With a strong emphasis on ethical standards and patient welfare, IRCCS Azienda Ospedaliero-Universitaria di Bologna plays a vital role in shaping the future of medicine through rigorous scientific inquiry and patient-centered care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bologna, , Italy
Patients applied
Trial Officials
Guido Di Dalmazi, MD
Principal Investigator
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported